个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Liu, Weiping[1] * ; Zhao, Donglu[2] ; Liu, Ting[3] ; Niu, Ting[3] ; Song, Yongping[4] ; Xu, Wei[5] ; Jin, Jie[6] ; Cai, Qingqing[7] ; Huang, Huiqiang[7] ; Li, Zhiming[7] ; Hou, Ming[8] ; Zhang, Huilai[9] ; Zhou, Jianfeng[10] ; Hu, Jianda[11] ; Shen, Jianzhen[11] ; Shi, Yuankai[12] ; Yang, Yu[13] ; Zhang, Liling[14] ; Zhao, Weili[15] ; Ding, Kaiyang[16] ; Qiu, Lugui[17] ; Tan, Huo[18] ; Zhang, Zhihui[19] ; Liu, Lihong[20] ; Wang, Jinghua[21] ; Xu, Bing[22] ; Zhou, Hui[23] ; Gao, Guangxun[24] ; Xue, Hongwei[25] ; Bai, Ou[26] ; Feng, Ru[27] ; Huang, Xiaobing[28,29] ; Yang, Haiyan[30] ; Yan, Xiaojing[31] ; Zeng, Qingshu[32] ; Liu, Peng[33] ; Li, Wenyu[34] ; Mao, Min[35] ; Su, Hang[36] ; Wang, Xin[37] ; Xu, Jingyan[38] ; Zhou, Daobin[39] ; Zhang, Hongyu[40] ; Ma, Jun[2] ; Shen, Zhixiang[15] ; Zhu, Jun[1] ;
单位： [1]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China [2]Harbin Inst Hematol & Oncol, Dept Hematol & Oncol, Harbin, Peoples R China [3]Sichuan Univ, Dept Hematol, West China Hosp, Chengdu, Peoples R China [4]Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China [5]Jiangsu Prov Hosp, Dept Hematol, Nanjing, Peoples R China [6]Zhejiang Univ, Dept Hematol, Affiliated Hosp 1, Hangzhou, Peoples R China [7]Sun Yat Sen Univ Canc Ctr, Dept Med Oncol, Guangzhou, Peoples R China [8]Shandong Univ, Dept Hematol, Qilu Hosp, Jinan, Peoples R China [9]Tianjin Med Univ Canc Inst & Hosp, Dept Lymphoma, Tianjin, Peoples R China [10]Huazhong Univ Sci AndTechnol, Dept Hematol, Tongji Hosp, Wuhan, Peoples R China [11]Fujian Med Univ, Dept Hematol, Affiliated Union Hosp, Fuzhou, Peoples R China [12]Chinese Acad Med Sci, Dept Med Oncol, Canc Inst & Hosp, Beijing, Peoples R China [13]Fujian Canc Hosp, Dept Lymphoma, Fuzhou, Peoples R China [14]Huazhong Univ Sci & Technol, Union Hosp, Dept Med Oncol, Tongji Med Coll, Wuhan, Peoples R China [15]Shanghai Rui Jin Hosp, Dept Hematol, Shanghai, Peoples R China [16]Anhui Prov Canc Hosp, Dept Hematol, Hefei, Peoples R China [17]Chinese Acad Med Sci, Dept Hematol, Hematol Inst & Hosp, Tianjin, Peoples R China [18]Guangzhou Med Univ, Dept Hematol, Affiliated Hosp 1, Guangzhou, Peoples R China [19]Sichuan Canc Hosp, Dept Med Oncol, Chengdu, Peoples R China [20]Hebei Med Univ, Dept Hematol, Hosp 4, Shijiazhuang, Hebei, Peoples R China [21]Nanjing Mil Command, Dept Med Oncol, Nanjing Gen Hosp, Nanjing, Peoples R China [22]Xiamen Univ, Dept Hematol, Affiliated Hosp 1, Xiamen, Peoples R China [23]Hunan Canc Hosp, Dept Lymphoma, Changsha, Peoples R China [24]Airforce Med Univ, Dept Hematol, Xijing Hosp, Xian, Peoples R China [25]Affiliated Hosp Qingdao Univ, Dept Lymphoma, Qingdao, Peoples R China [26]Jilin Univ, Dept Hematol, Bethune Hosp 1, Changchun, Peoples R China [27]Southern Med Univ, Dept Hematol, Nanfang Hosp, Guangzhou, Peoples R China [28]Sichuan Acad Med Sci, Dept Hematol, Chengdu, Peoples R China [29]Sichuan Prov Peoples Hosp, Chengdu, Peoples R China [30]Zhejiang Canc Hosp, Dept Lymphoma, Hangzhou, Peoples R China [31]China Med Univ, Dept Hematol, Hosp 1, Shenyang, Peoples R China [32]Anhui Med Univ, Dept Hematol, Affiliated Hosp 1, Hefei, Anhui, Peoples R China [33]Fudan Univ, Dept Hematol, Zhongshan Hosp, Shanghai, Peoples R China [34]Guangdong Prov Peoples Hosp, Dept Lymphoma, Guangzhou, Peoples R China [35]Peoples Hosp Xinjiang Uygur Autonomous Reg, Dept OfHematol, Urumqi, Peoples R China [36]Peoples Liberat Army PLA Gen Hosp, Dept Lymphoma, Med Ctr 5, Beijing, Peoples R China [37]Shandong First Med Univ, Dept Hematol, Affiliated Prov Hosp, Jinan, Peoples R China [38]Nanjing Univ, Dept Hematol, Nanjing Drum Tower Hosp, Med Sch, Nanjing, Peoples R China [39]Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China [40]Peking Univ, Dept Hematol, Shenzhen Hosp, Shenzhen, Peoples R China
出处：
DOI： 10.3389/fonc.2021.750323
ISSN：

关键词： lymphoma T-cell peripheral histone deacetylase inhibitors efficiency safety survival

摘要：
Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December 2017, 548 patients with R/R PTCL from 186 research centers in China were included in the study. Among the 261 patients treated with chidamide monotherapy, ORR was 58.6% and 55 patients (21.1%) achieved complete response (CR). Among the 287 patients receiving chidamide-containing combination therapies, ORR was 73.2% and 73 patients (25.4%) achieved CR. The median OS of all patients was 15.1 months. The median OS of patients receiving chidamide monotherapy and combination therapies was 433 and 463 days, respectively. These results demonstrate a significant survival advantage of chidamide treatments as compared with international historical records. Common adverse effects (AEs) were hematological toxicities. Most AEs in both monotherapy and combined treatments were grade 1-2. No unanticipated AEs occurred. In conclusion, chidamide-based therapy led to a favorable efficacy and survival benefit for R/R PTCL. Future studies should explore the potential advantage of chidamide treatment combined with chemotherapy.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版：
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区：
出版当年[2019]版：
Q2 ONCOLOGY
最新[2023]版：
Q2 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2019版] 出版当年五年平均 出版前一年[2018版] 出版后一年[2020版]

第一作者：
第一作者单位： [1]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Liu Weiping,Zhao Donglu,Liu Ting,et al.A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China[J].FRONTIERS IN ONCOLOGY.2021,11:doi:10.3389/fonc.2021.750323.
APA：
Liu, Weiping,Zhao, Donglu,Liu, Ting,Niu, Ting,Song, Yongping...&Zhu, Jun.(2021).A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.FRONTIERS IN ONCOLOGY,11,
MLA：
Liu, Weiping,et al."A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China".FRONTIERS IN ONCOLOGY 11.(2021)

相关文献

[1]Allogeneic Stem-Cell Transplantation for Peripheral T-Cell Lymphoma: A Systemic Review and Meta-Analysis [2]Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma [3]Autologous stem cell transplantation in tandem with Anti-CD30 CAR T-cell infusion in relapsed/refractory CD30(+) lymphoma [4]Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China [5]Kruppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells [6]Efficacy and safety of CAR19/22 T-cell "cocktail" therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma [7]Autologous Stem Cell Transplantation as the First-Line Treatment for Peripheral T Cell Lymphoma: Results of a Comprehensive Meta-Analysis [8]Reversion-inducing cysteine-rich protein with Kazal motifs gene expression and its clinical significance in peripheral T-cell lymphoma [9]Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial [10]Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial

资源点击量：432 今日访问量：0 总访问量：412 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）